Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02940886 · ClinicalTrials.gov registry record · Phase 3
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
A Phase 3 study, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,512
- Enrollment target
NCT02940886: Completed Phase 3 study, sponsored by Pharmacosmos A/S.
NCT02940886 is a Phase 3 study that has completed, run by Pharmacosmos A/S. The registered enrollment target is 1,512 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02940886, a Phase 3 study, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,512 participants
- Enrollment target
Study Summary
Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA.
Primary Outcome
Efficacy Evaluate the effect on the hemoglobin (Hb) level following treatment with iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with iron deficiency anaemia (IDA) . Response was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with IDA, when oral iron preparations were ineffective or could not be used or in whom the screening Hb measurement in Investigators' opinion were sufficiently low to require rapid repletion of ir
Interventions
- DRUG Iron sucrose
- DRUG Iron isomaltoside/ferric derisomaltose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,512 participants |
| Start Date | 2016-11-08 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 3 |
What the finished NCT02940886 record still lists
NCT02940886 is an interventional study that assigns participants to a tested intervention. Its 1,512 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% higher).
The record links to 0 conditions, and to 2 interventions - of which Iron sucrose is the first listed.
NCT02940886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02940886 about?
NCT02940886 is a clinical study titled "Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)". Evaluate safety and efficacy of iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®) compared with iron sucrose (Venofer®), in subjects diagnosed with IDA.
What is the current status of trial NCT02940886?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,512 participants. The study started on 2016-11-08. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT02940886?
The interventions under investigation include: Iron sucrose (DRUG), Iron isomaltoside/ferric derisomaltose (DRUG).
Who is sponsoring clinical trial NCT02940886?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02940886's enrollment target sits among peer trials
1,512 157th of 2000 higher than 1,844 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI